Earnings Releases·Nov 13, 2026, 8:35 AM ET

MetaVia — Third Quarter 2026 Earnings Summary

Total operating expenses rose to $4.7 million in Q3 2026 from $3.5 million in Q3 2025, driven by higher R&D costs for DA-1726 and increased G&A expenses, resulting in a net loss of $4.6 million ($0.69 per share) versus $3.4 million ($1.52 per share) in the prior year period.
Cash and cash equivalents decreased to $8.8 million as of September 30, 2026, from $10.3 million at year-end 2025, while weighted average shares outstanding increased significantly to 6.7 million from 2.2 million in Q3 2025.
Clinical progress includes Phase 1 Part 3B data for DA-1726 showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss, with full data expected in Q1 2027 and Phase 2 studies targeted for late 2027.
Management appointed Sarah Browne, M.D., as Chief Medical Officer in October 2026 and plans to schedule an FDA End-of-Phase 2 meeting for vanoglipel before the end of 2026.